文献速递慢性肾脏病肾血管病与高血压

前蛋白转化酶枯草溶菌素9在肾脏疾病中的作用

Proprotein convertase subtilisin/kexin type 9 in kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

综述指出慢性肾脏病(CKD)患者动脉粥样硬化性心血管风险显著增加,他汀和/或依折麦布是降脂基石但透析患者证据较弱。PCSK9抑制剂(evolocumab和alirocumab)可进一步降低LDL-C且心血管获益,但严重肾功能不全患者被排除在试验外,需专门研究。

要点

  • CKD早期即心血管死亡率增加,LDL-C参与动脉粥样硬化病变。
  • 他汀和/或依折麦布降脂证据充分,但维持性血液透析患者证据较弱。
  • PCSK9抑制剂降LDL-C疗效不受基线肾功能影响,但严重肾功能不全者被排除在试验外。

核心结论

  • PCSK9抑制剂可有效降低LDL-C并减少心血管事件,但严重肾功能不全CKD患者缺乏证据,需进一步专门研究。

研究设计与样本

  • 综述性文章,总结他汀/依折麦布及PCSK9抑制剂在CKD患者中的降脂证据与临床试验情况。

主要发现

  • 他汀治疗在肾功能正常和受损患者中均减少心血管事件,但维持性血液透析患者证据较弱。
  • evolocumab和alirocumab在最大耐受他汀基础上进一步降低LDL-C,无重大不良事件,且大型临床结局试验证实减少心血管事件。
  • PCSK9抑制剂的降LDL-C能力独立于基线肾功能,在中度CKD患者中有效。
  • 严重肾功能不全患者被排除在PCSK9抑制剂心血管结局试验之外。
  • PCSK9抑制剂降低脂蛋白(a)或改善肾病综合征血脂异常等非LDL依赖效应的相关性尚待确定。

关键数值与推荐

  • 他汀和/或依折麦布是降脂治疗的金标准,有大量大型临床试验证据。
  • evolocumab和alirocumab是目前获批的PCSK9抑制剂单克隆抗体。

临床怎么用

  • CKD患者应使用他汀和/或依折麦布作为基础降脂治疗。
  • 中度CKD患者可考虑PCSK9抑制剂进一步降低LDL-C,但严重肾功能不全者证据不足。

局限性

  • 严重肾功能不全(心血管风险最高)患者被排除在PCSK9抑制剂大型结局试验之外。
  • PCSK9抑制剂非LDL依赖效应(如降低脂蛋白(a))的临床相关性尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) is associated with a substantially increased risk for the development of atherosclerotic cardiovascular (CV) disease. Accordingly, CV mortality is increased even in the earliest stages of CKD. In the general population and in CKD patients, high plasma levels of low-density lipoprotein cholesterol (LDL-C) are crucially involved in the initiation and progression of atherosclerotic vascular lesions. Lowering LDL-C by use of statins and/or ezetimibe represents the gold standard of lipid-lowering therapy, with a great body of evidence from several large clinical trials. Statin therapy reduces CV events in patients with normal and impaired kidney function alike, while the evidence for patients on maintenance haemodialysis is weaker. The inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease represents a novel lipid-lowering tool. Currently the monoclonal antibodies evolocumab and alirocumab are the approved PCSK9 inhibitors. Despite maximum-tolerated statin therapy, they efficiently further reduce LDL-C plasma levels without any major adverse effects. Moreover, in large clinical outcome trials, both antibodies have been proven to lower CV events. Notably, the LDL-lowering capacity was independent of baseline kidney function and also efficient in patients with moderate CKD. However, patients with severely impaired kidney function, that is, the population at the highest CV risk, have been excluded from those trials. The relevance of the LDL-independent effects of PCSK9 inhibitors, such as lowering lipoprotein(a) or ameliorating dyslipidaemia in patients with nephrotic syndrome, has to be determined. Therefore further specific studies assessing the effects and outcomes of PCSK9-inhibiting treatment in CKD patients are warranted.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Schmit D, Fliser D, Speer T, et al. Proprotein convertase subtilisin/kexin type 9 in kidney disease. Nephrol Dial Transplant. 2019. PMID: 31190079. doi:10.1093/ndt/gfz122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。